3 Key Things Every CAR-T Investor Should Watch

A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.

First-to-market advantage will likely to go Novartis (NYSE: NVS) with its drug named CTL019. Recently, a panel of FDA advisors unanimously recommended approval for CTL019, which will likely receive a final stamp of approval from the agency by early October. Other notable CAR-T players will be following closely behind, such as Kite Pharma (NASDAQ: KITE) and Juno Therapeutics (NASDAQ: JUNO) as a multi-billion dollar oncology market is up for grabs.

Image source: Getty Images.

Source: Fool.com